Kiromic BioPharma, Inc. (KRBP)
| Previous close | 2.5000 |
| Open | 2.5500 |
| Bid | 0.0000 x 4000 |
| Ask | 0.0000 x 1800 |
| Day's range | 2.5500 - 2.6000 |
| 52-week range | 0.1600 - 8.9700 |
| Volume | |
| Avg. volume | 7,522 |
| Market cap | 3.349M |
| Beta (5Y monthly) | 2.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -12.5900 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireKiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
HOUSTON, April 02, 2024--Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
Business WireEarly Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
HOUSTON, March 19, 2024--Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") reports early efficacy results showing primary lung tumor stabilization and the complete disappearance of brain metastases in the second patient in the Company’s Deltacel-01 Phase 1 clinical trial. Deltacel-01 is evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC).
GlobeNewswireLife Science Virtual Investor Forum Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held March 7th are now available for online viewing. This event was sponsored by Zacks Small-Cap Research. REGISTER NOW AT: https://bit.ly/3T80zZl The company presentations will be available 24/7 for 90
